ARIA. ARIAD Announces Publication of Ponatinib Pha
Post# of 5789
ARIA. ARIAD Announces Publication of Ponatinib Phase 1 Clinical Trial Results in the New England Journal of Medicine
Results demonstrate that ponatinib is highly active in heavily pretreated patients with CML and Ph + ALL
http://phx.corporate-ir.net/phoenix.zhtml?c=1...highlight=
chart.